CoChat

Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer

Open access
Lokman, Noor A., Ho, Rachel, Gunasegaran, Kavyadharshini, Bonner, Wendy M., Oehler, Martin K., Ricciardelli, Carmela · 2019 · Journal of Experimental & Clinical Cancer Research

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Annexin A2 is increased in serous ovarian cancer and plays an essential role in ovarian cancer invasion and metastasis. In combination with S100A10, annexin A2 plays an important role in the plasminogen activator system regulating plasmin production. The aim of this study was to investigate the potential utility of all-trans retinoid acid (ATRA), an inhibitor of the annexin A2-S100A10 signalling pathway, as a new therapeutic against serous ovarian cancer. METHODS: In this study we determined the effects of ATRA treatment (1-5 μM) on annexin A2 and S100A10 expression, plasmin activation, and the ability of ATRA to inhibit serous ovarian cancer cell survival, motility and invasion in vitro. We also employed an ex vivo tissue explant assay to assess response to ATRA treatment in serous ovarian cancers. Cryopreserved serous ovarian cancer tissues were cultured on gelatin sponges for 72 h with ATRA (1 μM). Effects on apoptosis and proliferation were assessed by immunohistochemistry using antibodies to cleaved caspase 3 or Ki67, respectively. RESULTS: Survival of serous ovarian cancer cells (OVCAR-3, OV-90, & OAW28) was significantly decreased by ATRA treatment (1-5 μM). ATRA (1 μM) also significantly decreased proliferation (Ki67 positivity, p = 0.0034), S100A10 protein levels (p = 0.0273), and increased cell apoptosis (cleaved caspase-3 positivity, p = 0.0024) in serous ovarian cancer tissues using the ex vivo tissue explant assay. In OAW28 cells, reduced cell survival following ATRA treatment was associated with a reduction of S100A10 mRNA and protein levels, S100A10 and annexin A2 membrane localization, plasmin generation, motility and invasion. In contrast, ATRA inhibited OV-90 cell survival and invasion but did not affect plasmin activation or S100A10 and annexin A2 expression or membrane localization. CONCLUSIONS: These findings suggest that ATRA inhibits serous ovarian cancer proliferation and invasion via both S100A10 dependant and S100A10 independent mechanisms. Our results show that ATRA has promising potential as a novel therapy against serous ovarian cancer that warrants further evaluation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13046-018-1017-7

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The effect of ATRA treatment on serous ovarian cancer cell proliferation. Cell survival in response to 6 days ATRA treatment (1, 5 μM) is shown in order of cell invasiveness a OVCAR-3, b OAW28, c COV-318, d COV- 362, e OV-90 and primary serous ovarian cancer cells (n = 6) (f). Data are expressed as percentage of control, mean ± SEM from 3 to 4 independent experiments (20–24 determinations) in (a-e) and quadruplicate determinations for primary cells from 6 individual patients in (f). Statistical significance for a-e was determined using one-way ANOVA (Tukey multiple comparison post hoc test) and the paired Friedman test (Dunn’s multiple comparison test) for (f), *p < 0.05
Fig. 1 The effect of ATRA treatment on serous ovarian cancer cell proliferation. Cell survival in response to 6 days ATRA treatment (1, 5 μM) is shown in order of cell invasiveness a OVCAR-3, b OAW28, c COV-318, d COV- 362, e OV-90 and primary serous ovarian cancer cells (n = 6) (f). Data are expressed as percentage of control, mean ± SEM from 3 to 4 independent experiments (20–24 determinations) in (a-e) and quadruplicate determinations for primary cells from 6 individual patients in (f). Statistical significance for a-e was determined using one-way ANOVA (Tukey multiple comparison post hoc test) and the paired Friedman test (Dunn’s multiple comparison test) for (f), *p < 0.05CC BY · PubMed Central
Fig. 2 The effect of ATRA treatment on plasmin generation. Effect of 6 days ATRA treatment (5 μM) on plasmin activation in OAW28 (a), OV-90 (b), and OVCAR-3 (c) cells. Plg = plasminogen, ε-ACA = ε-aminocaproic acid. Data are the absorbance readings at 405 nm from 2 to 3 independent experiments (4–10 determinations). Statistical significance was determined using one-way ANOVA and the Tukey multiple comparison post hoc test, *p < 0.05
Fig. 2 The effect of ATRA treatment on plasmin generation. Effect of 6 days ATRA treatment (5 μM) on plasmin activation in OAW28 (a), OV-90 (b), and OVCAR-3 (c) cells. Plg = plasminogen, ε-ACA = ε-aminocaproic acid. Data are the absorbance readings at 405 nm from 2 to 3 independent experiments (4–10 determinations). Statistical significance was determined using one-way ANOVA and the Tukey multiple comparison post hoc test, *p < 0.05CC BY · PubMed Central
Fig. 3 Effect of ATRA treatment on motility and invasion. Effect of 6 days ATRA treatment (1, 5 μM) on motility and invasion of OAW28 (a) and OV-90 cells (b). Data are expressed as percentage of DMSO control, mean ± SEM from 3 to 5 independent experiments (10–20 determinations). Statistical significance was determined using one-way ANOVA and the Tukey multiple comparison post hoc test, *p < 0.05
Fig. 3 Effect of ATRA treatment on motility and invasion. Effect of 6 days ATRA treatment (1, 5 μM) on motility and invasion of OAW28 (a) and OV-90 cells (b). Data are expressed as percentage of DMSO control, mean ± SEM from 3 to 5 independent experiments (10–20 determinations). Statistical significance was determined using one-way ANOVA and the Tukey multiple comparison post hoc test, *p < 0.05CC BY · PubMed Central
Fig. 4 The effect of ATRA treatment on expression of ANXA2 and S100A10 mRNA and protein levels. The effect on ANXA2 and S100A10 expression following 1–6 days ATRA treatment (1, 5 μM) in OAW28 (a and c) and OV-90 (b and d) cells. ANXA2 and S100A10 expression was assessed using 2-∆∆CT quantitation method and normalised to housekeeping gene β-actin using no treatment control as a calibrator. Data is from 2 to 4 independent experiments (n = 4–12). Statistical significance was determined using one-way ANOVA and the Tukey multiple comparison post hoc test. Western blots for annexin A2 and S100A10 (e and f) following 6 days ATRA treatment (1, 5 μM). Annexin A2 bands at 38 kDa, S100A10 at 11 kDa and β-actin bands at 42 kDa are shown for OAW28 (e) and OV-90 (f) cells. Equal amounts protein (5 μg for annexin A2 & 15 μg S100A10 were run on a 4–12% SDS-PAGE gel and immunoblotted with mouse monoclonal antibodies to annexin A2 (1/2000, BD Biosciences) or S100A10 (1/2000, BD Biosciences). A rabbit polyclonal antibody was used detect β-actin (1/2000, ab8227, Abcam). Numbers below western bands in e and f are fold changes relative to the control treatment. Westerns blots are representative of two independent experiments
Fig. 4 The effect of ATRA treatment on expression of ANXA2 and S100A10 mRNA and protein levels. The effect on ANXA2 and S100A10 expression following 1–6 days ATRA treatment (1, 5 μM) in OAW28 (a and c) and OV-90 (b and d) cells. ANXA2 and S100A10 expression was assessed using 2-∆∆CT quantitation method and normalised to housekeeping gene β-actin using no treatment control as a calibrator. Data is from 2 to 4 independent experiments (n = 4–12). Statistical significance was determined using one-way ANOVA and the Tukey multiple comparison post hoc test. Western blots for annexin A2 and S100A10 (e and f) following 6 days ATRA treatment (1, 5 μM). Annexin A2 bands at 38 kDa, S100A10 at 11 kDa and β-actin bands at 42 kDa are shown for OAW28 (e) and OV-90 (f) cells. Equal amounts protein (5 μg for annexin A2 & 15 μg S100A10 were run on a 4–12% SDS-PAGE gel and immunoblotted with mouse monoclonal antibodies to annexin A2 (1/2000, BD Biosciences) or S100A10 (1/2000, BD Biosciences). A rabbit polyclonal antibody was used detect β-actin (1/2000, ab8227, Abcam). Numbers below western bands in e and f are fold changes relative to the control treatment. Westerns blots are representative of two independent experimentsCC BY · PubMed Central
Fig. 5 Effect of ATRA treatment on membrane localization of ANXA2 and S100A10 in OAW28 and OV-90 cells. ANXA2 and S100A10 immunofluorescence in OAW28 (a) and OV-90 (c) cells ± treatment with ATRA (5 μM). ANXA2 and S100A10 membrane localization is significantly reduced in OAW28 cells (b) but not OV-90 cells (d) following 6 days ATRA treatment. Data is expressed as mean % membrane positive cells ± SEM from 3 independent experiments. * p < 0.05 (unpaired student t test)
Fig. 5 Effect of ATRA treatment on membrane localization of ANXA2 and S100A10 in OAW28 and OV-90 cells. ANXA2 and S100A10 immunofluorescence in OAW28 (a) and OV-90 (c) cells ± treatment with ATRA (5 μM). ANXA2 and S100A10 membrane localization is significantly reduced in OAW28 cells (b) but not OV-90 cells (d) following 6 days ATRA treatment. Data is expressed as mean % membrane positive cells ± SEM from 3 independent experiments. * p < 0.05 (unpaired student t test)CC BY · PubMed Central
Fig. 6 The effect of ATRA treatment on proliferation and apoptosis in ex vivo tissue explants. High grade serous ovarian cancer tissues (n = 12) were treated with control medium (0.1% DMSO) or ATRA (1 μM) for 72 h. Apoptosis was assessed using an antibody to cleaved caspase 3 (a) and proliferation was assessed using Ki67 antibody (b). Representative images for cleaved caspase 3 and Ki67 are shown (scale bar = 100 μm, all images are the same magnification). The summary of the immunostaining quantitation for cleaved caspase 3 (a) and Ki67 (b) is shown. The data represents the number of Ki67 or cleaved caspase 3 positive cells/mm2 for each tissue. The bar is the median value. *p < 0.05, Wilcoxon pair test
Fig. 6 The effect of ATRA treatment on proliferation and apoptosis in ex vivo tissue explants. High grade serous ovarian cancer tissues (n = 12) were treated with control medium (0.1% DMSO) or ATRA (1 μM) for 72 h. Apoptosis was assessed using an antibody to cleaved caspase 3 (a) and proliferation was assessed using Ki67 antibody (b). Representative images for cleaved caspase 3 and Ki67 are shown (scale bar = 100 μm, all images are the same magnification). The summary of the immunostaining quantitation for cleaved caspase 3 (a) and Ki67 (b) is shown. The data represents the number of Ki67 or cleaved caspase 3 positive cells/mm2 for each tissue. The bar is the median value. *p < 0.05, Wilcoxon pair testCC BY · PubMed Central
Fig. 7 The effect of ATRA treatment on annexin A2 and S100A10 protein levels in ex vivo tissue explants. High grade serous ovarian cancer tissues were treated with control medium (0.1% DMSO) or ATRA (1 μM) for 72 h (n = 8). Representative images for annexin A2 (a) and S100A10 (b) immunostaining are shown (scale bar = 100 μm, all images are the same magnification). The summary of the annexin A2 and S100A10 immunostaining quantitation for 8 patients are shown. The data represents the area of annexin A2 or S100A10 positivity measured by video image analysis (% positive area). The bar is the median value. *p < 0.05, Wilcoxon pair test
Fig. 7 The effect of ATRA treatment on annexin A2 and S100A10 protein levels in ex vivo tissue explants. High grade serous ovarian cancer tissues were treated with control medium (0.1% DMSO) or ATRA (1 μM) for 72 h (n = 8). Representative images for annexin A2 (a) and S100A10 (b) immunostaining are shown (scale bar = 100 μm, all images are the same magnification). The summary of the annexin A2 and S100A10 immunostaining quantitation for 8 patients are shown. The data represents the area of annexin A2 or S100A10 positivity measured by video image analysis (% positive area). The bar is the median value. *p < 0.05, Wilcoxon pair testCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 45

Metadata

Authors
Lokman, N. A., Ho, R., Gunasegaran, K., Bonner, W. M., Oehler, M. K., & Ricciardelli, C.
Affiliations
  • The University of Adelaide (AU)
  • Royal Adelaide Hospital (AU)
  • Adelaide University (AU)
Corresponding author
Ricciardelli, Carmela
Venue
Journal of Experimental & Clinical Cancer Research
Published
2019-01-08
Volume
38
Issue
1
Pages
10-10
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W2917305526
Cited by
39
References
46
Citations by year
2026: 2 · 2025: 2 · 2024: 7 · 2023: 7 · 2022: 7 · 2021: 4 · 2020: 8 · 2019: 2
FWCI
5.02
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Cancer Council South Australia (N/A)
  • Ovarian Cancer Research Foundation (N/A)
Topics
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › S100 Proteins and Annexins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Keywords
all-trans retinoic acid, serous ovarian cancer, annexin A2, S100A10, plasminogen activation system, plasmin activation, tumor invasion, cell motility, apoptosis, cell proliferation, cancer therapy, OVCAR-3 cells
MeSH terms
Antineoplastic Agents, Cell Survival, Female, Humans, Ovarian Neoplasms, Tretinoin, Cystadenocarcinoma, Serous, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer. https://app.cochat.ai/papers/10.1186/s13046-018-1017-7
The paper
Lokman, N. A., Ho, R., Gunasegaran, K., Bonner, W. M., Oehler, M. K., & Ricciardelli, C. (2019). Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-018-1017-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.